Patient centricity

© Getty Images

FDA approval expands Welireg to patients with renal cell carcinoma

By Jonathan Smith

The oral treatment belzutifan, developed by MSD (known as Merck in the US) and branded as Welireg, has received the green light from the US Food and Drug Administration (FDA) for the treatment of an advanced form of renal cell carcinoma (RCC).